FY2027 Earnings Forecast for VKTX Issued By William Blair

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Stock analysts at William Blair issued their FY2027 earnings per share (EPS) estimates for Viking Therapeutics in a research note issued to investors on Wednesday, February 5th. William Blair analyst A. Hsieh anticipates that the biotechnology company will post earnings per share of ($2.42) for the year. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($0.97) per share.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same quarter last year, the firm posted ($0.25) earnings per share.

A number of other brokerages have also weighed in on VKTX. HC Wainwright restated a “buy” rating and issued a $102.00 price objective on shares of Viking Therapeutics in a report on Thursday. B. Riley reaffirmed a “buy” rating and set a $96.00 price target (down from $109.00) on shares of Viking Therapeutics in a report on Friday. StockNews.com upgraded Viking Therapeutics to a “sell” rating in a report on Tuesday, October 15th. Maxim Group decreased their target price on Viking Therapeutics from $120.00 to $70.00 and set a “buy” rating for the company in a research note on Friday. Finally, Raymond James increased their price target on shares of Viking Therapeutics from $122.00 to $125.00 and gave the company a “strong-buy” rating in a research note on Thursday. One analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $96.92.

Viking Therapeutics Stock Up 3.5 %

Shares of Viking Therapeutics stock opened at $32.56 on Friday. Viking Therapeutics has a 52-week low of $25.34 and a 52-week high of $99.41. The company has a market capitalization of $3.63 billion, a P/E ratio of -35.01 and a beta of 0.90. The company has a 50 day moving average of $40.05 and a 200 day moving average of $53.88.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Blue Trust Inc. acquired a new stake in Viking Therapeutics in the third quarter valued at about $26,000. GAMMA Investing LLC raised its stake in shares of Viking Therapeutics by 124.6% during the 3rd quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock worth $28,000 after buying an additional 243 shares in the last quarter. Gilliland Jeter Wealth Management LLC acquired a new stake in shares of Viking Therapeutics in the 3rd quarter valued at approximately $32,000. Stone House Investment Management LLC boosted its stake in shares of Viking Therapeutics by 66.7% in the third quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 200 shares in the last quarter. Finally, YANKCOM Partnership acquired a new position in Viking Therapeutics during the fourth quarter worth $33,000. 76.03% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Greg Zante sold 50,309 shares of Viking Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $42.75, for a total value of $2,150,709.75. Following the transaction, the chief financial officer now directly owns 165,259 shares in the company, valued at $7,064,822.25. This trade represents a 23.34 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Brian Lian sold 194,490 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $42.75, for a total transaction of $8,314,447.50. Following the transaction, the chief executive officer now owns 2,366,570 shares of the company’s stock, valued at approximately $101,170,867.50. The trade was a 7.59 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 299,014 shares of company stock valued at $12,782,849. Insiders own 4.70% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.